114 related articles for article (PubMed ID: 20405849)
1. Liposomal formulation of retinoids designed for enzyme triggered release.
Pedersen PJ; Adolph SK; Subramanian AK; Arouri A; Andresen TL; Mouritsen OG; Madsen R; Madsen MW; Peters GH; Clausen MH
J Med Chem; 2010 May; 53(9):3782-92. PubMed ID: 20405849
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs.
Pedersen PJ; Christensen MS; Ruysschaert T; Linderoth L; Andresen TL; Melander F; Mouritsen OG; Madsen R; Clausen MH
J Med Chem; 2009 May; 52(10):3408-15. PubMed ID: 19402667
[TBL] [Abstract][Full Text] [Related]
3. Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs.
Arouri A; Mouritsen OG
Eur J Pharm Sci; 2012 Mar; 45(4):408-20. PubMed ID: 21946258
[TBL] [Abstract][Full Text] [Related]
4. Anticancer double lipid prodrugs: liposomal preparation and characterization.
Arouri A; Mouritsen OG
J Liposome Res; 2011 Dec; 21(4):296-305. PubMed ID: 21438721
[TBL] [Abstract][Full Text] [Related]
5. Liposomes containing alkylated methotrexate analogues for phospholipase A(2) mediated tumor targeted drug delivery.
Kaasgaard T; Andresen TL; Jensen SS; Holte RO; Jensen LT; Jørgensen K
Chem Phys Lipids; 2009 Feb; 157(2):94-103. PubMed ID: 19094974
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin phospholipid conjugates with unusual biophysical and cytotoxic properties.
Pedersen PJ; Adolph SK; Andresen TL; Madsen MW; Madsen R; Clausen MH
Bioorg Med Chem Lett; 2010 Aug; 20(15):4456-8. PubMed ID: 20591667
[TBL] [Abstract][Full Text] [Related]
7. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic study of the sPLA2-mediated hydrolysis of a thio-ester pro anticancer ether lipid.
Linderoth L; Fristrup P; Hansen M; Melander F; Madsen R; Andresen TL; Peters GH
J Am Chem Soc; 2009 Sep; 131(34):12193-200. PubMed ID: 19663381
[TBL] [Abstract][Full Text] [Related]
9. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
11. Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment.
Jin Y; Yang F; Du L
Colloids Surf B Biointerfaces; 2013 Dec; 112():421-8. PubMed ID: 24036626
[TBL] [Abstract][Full Text] [Related]
12. Drug delivery by an enzyme-mediated cyclization of a lipid prodrug with unique bilayer-formation properties.
Linderoth L; Peters GH; Madsen R; Andresen TL
Angew Chem Int Ed Engl; 2009; 48(10):1823-6. PubMed ID: 19173369
[TBL] [Abstract][Full Text] [Related]
13. Liposomal Formulation of a PLA2-Sensitive Phospholipid-Allocolchicinoid Conjugate: Stability and Activity Studies In Vitro.
Kobanenko MK; Tretiakova DS; Shchegravina ES; Antipova NV; Boldyrev IA; Fedorov AY; Vodovozova EL; Onishchenko NR
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162957
[TBL] [Abstract][Full Text] [Related]
14. Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles.
Forrest ML; Zhao A; Won CY; Malick AW; Kwon GS
J Control Release; 2006 Nov; 116(2):139-49. PubMed ID: 16926059
[TBL] [Abstract][Full Text] [Related]
15. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
Andresen TL; Jensen SS; Kaasgaard T; Jørgensen K
Curr Drug Deliv; 2005 Oct; 2(4):353-62. PubMed ID: 16305438
[TBL] [Abstract][Full Text] [Related]
16. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability.
Padamwar MN; Pokharkar VB
Int J Pharm; 2006 Aug; 320(1-2):37-44. PubMed ID: 16707237
[TBL] [Abstract][Full Text] [Related]
17. Theoretical Assessment of Fluorinated Phospholipids in the Design of Liposomal Drug-Delivery Systems.
Madsen JJ; Fristrup P; Peters GH
J Phys Chem B; 2016 Sep; 120(36):9661-71. PubMed ID: 27557037
[TBL] [Abstract][Full Text] [Related]
18. Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs.
Mittal S; Song X; Vig BS; Landowski CP; Kim I; Hilfinger JM; Amidon GL
Mol Pharm; 2005; 2(1):37-46. PubMed ID: 15804176
[TBL] [Abstract][Full Text] [Related]
19. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
McNeeley KM; Karathanasis E; Annapragada AV; Bellamkonda RV
Biomaterials; 2009 Aug; 30(23-24):3986-95. PubMed ID: 19427688
[TBL] [Abstract][Full Text] [Related]
20. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy.
Pradhan P; Giri J; Rieken F; Koch C; Mykhaylyk O; Döblinger M; Banerjee R; Bahadur D; Plank C
J Control Release; 2010 Feb; 142(1):108-21. PubMed ID: 19819275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
